Evolocumab 降低低密度脂蛋白胆固醇有效性与安全性的 Meta 分析

摘要

Objective To evaluate the efficacy and safety of Evolocumab for lowering low density lipoprotein cholesterol (LDL-C ). Methods Electronic databases were searched to identify all randomized controlled trials comparing Evolocumab and palcebo for hypercholesterolaemia patients.Software RevMan 5.2 was utilized to perform Meta analysis.Results The study enrolled five studies including 1 396 patients.Compared with the placebo group, Evolocumab reduced LDL-C significantly (WMD=-55.04,95% CI =-57.45-52.62,P 3 upper limits of normal (ULN),creatinine kinase >5 ULN (OR =2.52,95% CI =0.63-10.00),severe adverse event (OR =1.49, 95% CI =0.82-2.73,P =0.1 9),discontinuation of investigational product due to adverse event (OR =1.1 7,95% CI=0.5 1-2.72)(P >0.05).Conclusion This meta-analysis suggests that Evolocumab is effective and safe for patients with hypercholesterolaemia.%目的：评价 Evolocumab 降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)的有效性及安全性。方法通过电子数据库检索所有评价 Evolocumab 治疗高 LDL-C 的随机对照研究,采用 RevMan5.2软件对数据进行 Meta 分析。结果一共纳入5项前瞻性随机对照研究,包括1396个病例。Meta 分析结果显示：与安慰剂比较,Evolocumab 可显著降低 LDL-C(WMD=-55.04,95% CI =-57.45~-52.62,P 0.05)。结论现有临床试验数据表明, Evolocumab 降低 LDL-C 是安全有效的。